Search

Your search keyword '"Baraibar, Iosune"' showing total 172 results
Start Over Author "Baraibar, Iosune"
172 results on '"Baraibar, Iosune"'

1. Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab

Author

Genova, Carlo, Marconi, Silvia, Chiorino, Giovanna, Guana, Francesca, Ostano, Paola, Santamaria, Sara, Rossi, Giovanni, Vanni, Irene, Longo, Luca, Tagliamento, Marco, Zullo, Lodovica, Dal Bello, Maria Giovanna, Dellepiane, Chiara, Alama, Angela, Rijavec, Erika, Ludovini, Vienna, Barletta, Giulia, Passiglia, Francesco, Metro, Giulio, Baglivo, Sara, Chiari, Rita, Rivoltini, Licia, Biello, Federica, Baraibar, Iosune, Gil-Bazo, Ignacio, Novello, Silvia, Grossi, Francesco, and Coco, Simona

Published
2024
Full Text
View/download PDF

3. Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment

Author

Cabrero-de las Heras, Sara, Hernández-Yagüe, Xavier, González, Andrea, Losa, Ferran, Soler, Gemma, Bugés, Cristina, Baraibar, Iosune, Esteve, Anna, Pardo-Cea, Miguel Ángel, Ree, Anne Hansen, Martínez-Bosch, Neus, Nieva, Maria, Musulén, Eva, Meltzer, Sebastian, Lobato, Tania, Vendrell-Ayats, Carla, Queralt, Cristina, Navarro, Pilar, Montagut, Clara, Grau-Leal, Ferran, Camacho, David, Legido, Raquel, Mulet-Margalef, Núria, and Martínez-Balibrea, Eva

Published
2024
Full Text
View/download PDF

6. Real-World Data of Patients with BRAF V600E-Mutated Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil.

Author

Ros, Javier, Ucha, Jose Maria, Garcia-Galea, Eduardo, Gomez, Pablo, Martini, Giulia, Balconi, Francesca, Comas, Raquel, Alonso, Vicente, Rodriguez, Marta, Baraibar, Iosune, Salva, Francesc, Saoudi, Nadia, Alcaraz, Adriana, Garcia, Ariadna, Tabernero, Josep, and Elez, Elena

Subjects
THERAPEUTIC use of antineoplastic agents, ANEMIA, ASTHENIA, COLORECTAL cancer, TREATMENT effectiveness, RETROSPECTIVE studies, METASTASIS, DEOXYRIBONUCLEOSIDES, MEDICAL records, ACQUISITION of data, SURVIVAL analysis (Biometry), PROGRESSION-free survival, NEUTROPENIA
Abstract

Simple Summary: Trifluridine/tipiracil (FTD–TPI) is a therapy for metastatic colorectal cancer after progression on standard treatment. Some patients with colorectal cancer harbor a BRAF gene mutation and may not respond as well to treatment compared to patients without this mutation. We evaluated patients with a BRAF mutated colorectal cancer treated with FTD–TPI as part of routine hospital care. Survival for these patients was 6.6 months, with disease progression after 2.3 months. Patients' functional status (according to a standardized scale "ECOG") stands as the most relevant factor guiding survival outcome; patients with a better status (ECOG 0) survived for longer than patients with poorer status (ECOG 2; 12 months vs. less than 2 months, respectively). Side effects with FTD-TPI were equivalent to those reported for the overall colorectal cancer population. This study suggests that FTD–TPI remains a therapeutic option for selected patients with BRAF mCRC. Background: For patients with refractory metastatic colorectal cancer (mCRC), trifluridine/tipiracil (FTD–TPI) has been associated with a significant improvement in overall survival (OS). However, data are lacking regarding the activity of FTD–TPI in patients with BRAF-mutated mCRC. Methods: This retrospective, multicenter, international cohort included patients with BRAF-mutated mCRC treated with FTD–TPI in a real-life setting in Spain and Italy. Survival analysis was performed using Kaplan–Meier methods and Cox proportional hazard models and according to established prognostic groups: good prognosis characteristics (GPC; < 3 metastatic sites and time from metastases to FTD–TPI ≥ 18 months) and poor prognosis characteristics (PPC; ≥ 3 metastatic sites or time from metastases to FTD–TPI < 18 months). Results: In the 26 patients included, the median age was 61 years, 13 (50%) were female, and 20 (77%) had an Eastern Cooperative Oncology Group (ECOG) performance status of 1. Fourteen (56%) patients had right-sided tumors, six (23%) had microsatellite instability tumors, and thirteen (50%) had liver metastases. Median progression-free survival was 2.3 months (95% CI 2.0–3.2), and median OS (mOS) was 6.6 months (95% CI 4.4–12.0). mOS was 7.6 vs. 4.2 months (HR 1.64, 95% CI 0.65–4.10, p = 0.3) for GPC and PPC patients, respectively. Exploratory analyses identified ECOG as the only feature associated with survival. The most frequent grade 3–4 adverse events were neutropenia (8%), anemia (8%), and asthenia (4%). Conclusions: Patients with BRAF mutant mCRC achieved modest benefits with FTD–TPI; however, patients with GPC and ECOG 0 achieved longer OS compared with those with PPC or ECOG 1–2, thus warranting further exploration in prospective cohorts. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy

Author

González, Nadia Saoudi, primary, Marchese, Paola Valeria, additional, Baraibar, Iosune, additional, Ros, Javier, additional, Salvà, Francesc, additional, Rodríguez, Marta, additional, Salvà, Clara, additional, Vaghi, Caterina, additional, Alcaraz, Adriana, additional, García, Ariadna, additional, Tabernero, Josep, additional, and Élez, Elena, additional

Published
2024
Full Text
View/download PDF

12. Changes in serum CXCL13 levels are associated with outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment

Author

Cabrero-de las Heras, Sara, primary, Hernández-Yagüe, Xavier, additional, González, Andrea, additional, Losa, Ferran, additional, Soler, Gemma, additional, Bugés, Cristina, additional, Baraibar, Iosune, additional, Esteve, Anna, additional, Pardo-Cea, Miguel Ángel, additional, Ree, Anne Hansen, additional, Martínez-Bosch, Neus, additional, Nieva, Maria, additional, Musulén, Eva, additional, Meltzer, Sebastian, additional, Lobato, Tania, additional, Vendrell-Ayats, Carla, additional, Queralt, Cristina, additional, Navarro, Pilar, additional, Montagut, Clara, additional, Grau-Leal, Ferran, additional, Camacho, David, additional, Legido, Raquel, additional, Mulet-Margalef, Núria, additional, and Martínez-Balibrea, Eva, additional

Published
2024
Full Text
View/download PDF

14. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

Author

Duruisseaux, Michäel, Martínez-Cardús, Anna, Calleja-Cervantes, Maria E, Moran, Sebastian, Castro de Moura, Manuel, Davalos, Veronica, Piñeyro, David, Sanchez-Cespedes, Montse, Girard, Nicolas, Brevet, Marie, Giroux-Leprieur, Etienne, Dumenil, Coraline, Pradotto, Monica, Bironzo, Paolo, Capelletto, Enrica, Novello, Silvia, Cortot, Alexis, Copin, Marie-Christine, Karachaliou, Niki, Gonzalez-Cao, Maria, Peralta, Sergio, Montuenga, Luis M, Gil-Bazo, Ignacio, Baraibar, Iosune, Lozano, Maria D, Varela, Mar, Ruffinelli, Jose C, Palmero, Ramon, Nadal, Ernest, Moran, Teresa, Perez, Lidia, Ramos, Immaculada, Xiao, Qingyang, Fernandez, Agustin F, Fraga, Mario F, Gut, Marta, Gut, Ivo, Teixidó, Cristina, Vilariño, Noelia, Prat, Aleix, Reguart, Noemi, Benito, Amparo, Garrido, Pilar, Barragan, Isabel, Emile, Jean-François, Rosell, Rafael, Brambilla, Elisabeth, and Esteller, Manel

Published
2018
Full Text
View/download PDF

16. The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche

Author

Castañón, Eduardo, Soltermann, Alex, López, Inés, Román, Marta, Ecay, Margarita, Collantes, María, Redrado, Miriam, Baraibar, Iosune, López-Picazo, José María, Rolfo, Christian, Vidal-Vanaclocha, Fernando, Raez, Luis, Weder, Walter, Calvo, Alfonso, and Gil-Bazo, Ignacio

Published
2017
Full Text
View/download PDF

21. Impact of the COVID-19 pandemic in the early-onset colorectal cancer

Author

Baraibar, Iosune, primary, García, Ariadna, additional, Salvà, Francesc, additional, Ros, Javier, additional, Saoudi, Nadia, additional, Comas, Raquel, additional, Castillo, Gloria, additional, Sanchis, Mireia, additional, García-Álvarez, Alejandro, additional, Hernando, Jorge, additional, Capdevila, Jaume, additional, Castells, Marta R, additional, Martí, Marc, additional, Landolfi, Stefania, additional, Espín, Eloy, additional, Navalpotro, Begoña, additional, Guevara, Jorge, additional, Dopazo, Cristina, additional, Nuciforo, Paolo, additional, Vivancos, Ana, additional, Tabernero, Josep, additional, and Élez, Elena, additional

Published
2023
Full Text
View/download PDF

22. Abstract 4577: An innovative platform to mimic the tumoral vascular microenvironment (TME) of patients with metastatic colorectal cancer (mCRC) using bioprinted hydrogel microfluidics

Author

González, Nadia Saoudi, primary, Ballabrera, Francesc Salvà, additional, García, Ariadna, additional, Gonzalo-Ruiz, Javier, additional, Baraibar, Iosune, additional, Ros, Javier, additional, Rodriguez, Marta, additional, Díaz, María García, additional, Fusté, Marta Falcó, additional, Kashani, Melika Parchehbaf, additional, Honrado, Carlos, additional, Ainla, Alar, additional, Tabernero, Josep, additional, Diéguez, Lorena, additional, Fraiz, Elena Martínez, additional, and Élez, Elena, additional

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 3 from Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network

Author

Román, Marta, primary, López, Inés, primary, Guruceaga, Elisabeth, primary, Baraibar, Iosune, primary, Ecay, Margarita, primary, Collantes, María, primary, Nadal, Ernest, primary, Vallejo, Adrián, primary, Cadenas, Silvia, primary, Miguel, Marta Echavarri-de, primary, Jang, Jae Hwi, primary, Martin-Uriz, Patxi San, primary, Castro-Labrador, Laura, primary, Vilas-Zornoza, Amaia, primary, Lara-Astiaso, David, primary, Ponz-Sarvise, Mariano, primary, Rolfo, Christian, primary, Santos, Edgardo S., primary, Raez, Luis E., primary, Taverna, Simona, primary, Behrens, Carmen, primary, Weder, Walter, primary, Wistuba, Ignacio I., primary, Vicent, Silvestre, primary, and Gil-Bazo, Ignacio, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 1 from Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network

Author

Román, Marta, primary, López, Inés, primary, Guruceaga, Elisabeth, primary, Baraibar, Iosune, primary, Ecay, Margarita, primary, Collantes, María, primary, Nadal, Ernest, primary, Vallejo, Adrián, primary, Cadenas, Silvia, primary, Miguel, Marta Echavarri-de, primary, Jang, Jae Hwi, primary, Martin-Uriz, Patxi San, primary, Castro-Labrador, Laura, primary, Vilas-Zornoza, Amaia, primary, Lara-Astiaso, David, primary, Ponz-Sarvise, Mariano, primary, Rolfo, Christian, primary, Santos, Edgardo S., primary, Raez, Luis E., primary, Taverna, Simona, primary, Behrens, Carmen, primary, Weder, Walter, primary, Wistuba, Ignacio I., primary, Vicent, Silvestre, primary, and Gil-Bazo, Ignacio, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Data from Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study

Author

Kagawa, Yoshinori, primary, Elez, Elena, primary, García-Foncillas, Jesús, primary, Bando, Hideaki, primary, Taniguchi, Hiroya, primary, Vivancos, Ana, primary, Akagi, Kiwamu, primary, García, Ariadna, primary, Denda, Tadamichi, primary, Ros, Javier, primary, Nishina, Tomohiro, primary, Baraibar, Iosune, primary, Komatsu, Yoshito, primary, Ciardiello, Davide, primary, Oki, Eiji, primary, Kudo, Toshihiro, primary, Kato, Takeshi, primary, Yamanaka, Takeharu, primary, Tabernero, Josep, primary, and Yoshino, Takayuki, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 2 from Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network

Author

Román, Marta, primary, López, Inés, primary, Guruceaga, Elisabeth, primary, Baraibar, Iosune, primary, Ecay, Margarita, primary, Collantes, María, primary, Nadal, Ernest, primary, Vallejo, Adrián, primary, Cadenas, Silvia, primary, Miguel, Marta Echavarri-de, primary, Jang, Jae Hwi, primary, Martin-Uriz, Patxi San, primary, Castro-Labrador, Laura, primary, Vilas-Zornoza, Amaia, primary, Lara-Astiaso, David, primary, Ponz-Sarvise, Mariano, primary, Rolfo, Christian, primary, Santos, Edgardo S., primary, Raez, Luis E., primary, Taverna, Simona, primary, Behrens, Carmen, primary, Weder, Walter, primary, Wistuba, Ignacio I., primary, Vicent, Silvestre, primary, and Gil-Bazo, Ignacio, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 4 from Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network

Author

Román, Marta, primary, López, Inés, primary, Guruceaga, Elisabeth, primary, Baraibar, Iosune, primary, Ecay, Margarita, primary, Collantes, María, primary, Nadal, Ernest, primary, Vallejo, Adrián, primary, Cadenas, Silvia, primary, Miguel, Marta Echavarri-de, primary, Jang, Jae Hwi, primary, Martin-Uriz, Patxi San, primary, Castro-Labrador, Laura, primary, Vilas-Zornoza, Amaia, primary, Lara-Astiaso, David, primary, Ponz-Sarvise, Mariano, primary, Rolfo, Christian, primary, Santos, Edgardo S., primary, Raez, Luis E., primary, Taverna, Simona, primary, Behrens, Carmen, primary, Weder, Walter, primary, Wistuba, Ignacio I., primary, Vicent, Silvestre, primary, and Gil-Bazo, Ignacio, primary

Published
2023
Full Text
View/download PDF

28. Data from Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network

Author

Román, Marta, primary, López, Inés, primary, Guruceaga, Elisabeth, primary, Baraibar, Iosune, primary, Ecay, Margarita, primary, Collantes, María, primary, Nadal, Ernest, primary, Vallejo, Adrián, primary, Cadenas, Silvia, primary, Miguel, Marta Echavarri-de, primary, Jang, Jae Hwi, primary, Martin-Uriz, Patxi San, primary, Castro-Labrador, Laura, primary, Vilas-Zornoza, Amaia, primary, Lara-Astiaso, David, primary, Ponz-Sarvise, Mariano, primary, Rolfo, Christian, primary, Santos, Edgardo S., primary, Raez, Luis E., primary, Taverna, Simona, primary, Behrens, Carmen, primary, Weder, Walter, primary, Wistuba, Ignacio I., primary, Vicent, Silvestre, primary, and Gil-Bazo, Ignacio, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Information from Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network

Author

Román, Marta, primary, López, Inés, primary, Guruceaga, Elisabeth, primary, Baraibar, Iosune, primary, Ecay, Margarita, primary, Collantes, María, primary, Nadal, Ernest, primary, Vallejo, Adrián, primary, Cadenas, Silvia, primary, Miguel, Marta Echavarri-de, primary, Jang, Jae Hwi, primary, Martin-Uriz, Patxi San, primary, Castro-Labrador, Laura, primary, Vilas-Zornoza, Amaia, primary, Lara-Astiaso, David, primary, Ponz-Sarvise, Mariano, primary, Rolfo, Christian, primary, Santos, Edgardo S., primary, Raez, Luis E., primary, Taverna, Simona, primary, Behrens, Carmen, primary, Weder, Walter, primary, Wistuba, Ignacio I., primary, Vicent, Silvestre, primary, and Gil-Bazo, Ignacio, primary

Published
2023
Full Text
View/download PDF

31. Identification and external validation of clinical-molecular features to predict benefit from oxaliplatin reintroduction/rechallenge in patients with refractory metastatic colorectal cancer (mCRC).

Author

Salva, Francesc, primary, Paes, Rafael, additional, Costa e Silva, Matheus, additional, Cruz, Heloisa, additional, Saoudi Gonzalez, Nadia, additional, Baraibar, Iosune, additional, Ros Montañá, Javier, additional, Comas, Raquel, additional, Ruiz-Pace, Fiorella, additional, Garcia, Ariadna, additional, Dalpino, Renata, additional, Jácome, Alexandre A., additional, Tabernero, Josep, additional, Elez, Elena, additional, and Dienstmann, Rodrigo, additional

Published
2023
Full Text
View/download PDF

32. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy

Author

Élez, Elena, primary, Mulet-Margalef, Núria, additional, Sanso, Miriam, additional, Ruiz-Pace, Fiorella, additional, Mancuso, Francesco M., additional, Comas, Raquel, additional, Ros, Javier, additional, Argilés, Guillem, additional, Martini, Giulia, additional, Sanz-Garcia, Enrique, additional, Baraibar, Iosune, additional, Salvà, Francesc, additional, Noguerido, Alba, additional, Cuadra-Urteaga, Jose Luis, additional, Fasani, Roberta, additional, Garcia, Ariadna, additional, Jimenez, Jose, additional, Aguilar, Susana, additional, Landolfi, Stefania, additional, Hernández-Losa, Javier, additional, Braña, Irene, additional, Nuciforo, Paolo, additional, Dienstmann, Rodrigo, additional, Tabernero, Josep, additional, Salazar, Ramon, additional, and Vivancos, Ana, additional

Published
2022
Full Text
View/download PDF

35. Abstract 3489: Luminex-based analysis of serum CXC chemokines showing their usefulness as prognostic and/or predictive biomarkers in metastatic colorectal cancer patients

Author

Cabrero-de las Heras, Sara, primary, Losa, Ferran, additional, Hernández-Yagüe, Xavier, additional, Soler, Gemma, additional, Bugés, Cristina, additional, Baraibar, Iosune, additional, Plaja, Andrea, additional, Teixidor, Eduard, additional, and Martínez-Balibrea, Eva, additional

Published
2022
Full Text
View/download PDF

37. Impact of circulating tumor DNA (ctDNA) mutant allele fraction in response to anti-angiogenic therapy in RAS-mutant metastatic colorectal cancer (mCRC): Clinical data in the first-line setting and correlation in patient-derived xenograft (PDX) models.

Author

Saoudi Gonzalez, Nadia, primary, Ros Montañá, Javier, additional, Martini, Giulia, additional, Comas, Raquel, additional, Garcia, Ariadna, additional, Baraibar, Iosune, additional, Salva, Francesc, additional, Laia, Cabellos, additional, Castillo, Gloria, additional, Navarro Garces, Victor, additional, Perez-Lopez, Raquel, additional, Palmer, Hector G., additional, Vivancos, Ana, additional, Tabernero, Josep, additional, and Elez, Elena, additional

Published
2022
Full Text
View/download PDF

42. A Comprehensive Biomarker Analysis of Microsatellite Unstable/Mismatch Repair Deficient Colorectal Cancer Cohort Treated with Immunotherapy.

Author

Élez, Elena, Mulet-Margalef, Núria, Sanso, Miriam, Ruiz-Pace, Fiorella, Mancuso, Francesco M., Comas, Raquel, Ros, Javier, Argilés, Guillem, Martini, Giulia, Sanz-Garcia, Enrique, Baraibar, Iosune, Salvà, Francesc, Noguerido, Alba, Cuadra-Urteaga, Jose Luis, Fasani, Roberta, Garcia, Ariadna, Jimenez, Jose, Aguilar, Susana, Landolfi, Stefania, and Hernández-Losa, Javier

Subjects
COLORECTAL cancer, DNA mismatch repair, BIOMARKERS, PROGRAMMED cell death 1 receptors, T cells, MICROSATELLITE repeats, PROGRAMMED death-ligand 1, POLYMERASE chain reaction
Abstract

The search for immunotherapy biomarkers in Microsatellite Instability High/Deficient Mismatch Repair system (MSI-H/dMMR) metastatic colorectal cancer (mCRC) is an unmet need. Sixteen patients with mCRC and MSI-H/dMMR (determined by either immunohistochemistry or polymerase chain reaction) treated with PD-1/PD-L1 inhibitors at our institution were included. According to whether the progression-free survival with PD-1/PD-L1 inhibitors was longer than 6 months or shorter, patients were clustered into the IT-responder group (n: 9 patients) or IT-resistant group (n: 7 patients), respectively. In order to evaluate determinants of benefit with PD-1/PD-L1 inhibitors, we performed multimodal analysis including genomics (through NGS panel tumour-only with 431 genes) and the immune microenvironment (using CD3, CD8, FOXP3 and PD-L1 antibodies). The following mutations were more frequent in IT-resistant compared with IT-responder groups: B2M (4/7 versus 2/9), CTNNB1 (2/7 versus 0/9), and biallelic PTEN (3/7 versus 1/9). Biallelic ARID1A mutations were found exclusively in the IT-responder group (4/9 patients). Tumour mutational burden did not correlate with immunotherapy benefit, neither the rate of indels in homopolymeric regions. Of note, biallelic ARID1A mutated tumours had the highest immune infiltration and PD-L1 scores, contrary to tumours with CTNNB1 mutation. Immune microenvironment analysis showed higher densities of different T cell subpopulations and PD-L1 expression in IT-responders. Misdiagnosis of MSI-H/dMMR inferred by discordances between immunohistochemistry and polymerase chain reaction was only found in the IT-resistant population (3/7 patients). Biallelic ARID1A mutations and Wnt signalling activation through CTNNB1 mutation were associated with high and low T cell immune infiltrates, respectively, and deserve special attention as determinants of response to PD-1/PD-L1 inhibitors. The non-MSI-H phenotype in dMMR is associated with poor benefit to immunotherapy. Our results suggest that mechanisms of resistance to immunotherapy are multi-factorial. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

43. Up-to-date role of aflibercept in the treatment of colorectal cancer

Author

Saoudi Gonzalez, Nadia, primary, Salvà, Francesc, additional, Ros, Javier, additional, Baraibar, Iosune, additional, Marmolejo, David, additional, Valdivia, Augusto, additional, Cuadra-Urteaga, Jose Luis, additional, Mulet, Nuria, additional, Tabernero, Josep, additional, and Élez, Elena, additional

Published
2021
Full Text
View/download PDF

44. ItRECIST adapted efficacy assessment in solid tumors treated with intratumoral immunotherapy.

Author

Oberoi, Honey Kumar, primary, Serres-Créixams, Xavier, additional, Alonso, Guzman, additional, Matos, Ignacio, additional, Hernando-Calvo, Alberto, additional, Muñoz-Couselo, Eva, additional, Diez, Marc, additional, Baraibar, Iosune, additional, Vieito, Maria, additional, Saavedra Santa Gadea, Omar, additional, Galvao, Vladimir, additional, Mur-Bonet, Gemma, additional, Cunill-Macià, Guillem, additional, Oliveira, Mafalda, additional, Felip, Enriqueta, additional, Macarulla, Teresa, additional, Elez, Elena, additional, Tabernero, Josep, additional, Brana, Irene, additional, and Garralda, Elena, additional

Published
2021
Full Text
View/download PDF

45. Young-onset colorectal cancer: A call for action.

Author

Baraibar, Iosune, primary, Salva, Francesc, additional, Comas, Raquel, additional, Ros, Javier, additional, Garcia, Ariadna, additional, Sanchis, Mireia, additional, Cuadra, Jose Luis, additional, Saoudi, Nadia, additional, Valdivia, Augusto, additional, Mulet, Nuria, additional, Virgili, Ana, additional, Hernando, Jorge, additional, Capdevila, Jaume, additional, Martí, Marc, additional, Landolfi, Stefania, additional, Verdaguer, Helena, additional, Espin, Eloy, additional, Nuciforo, Paolo, additional, Tabernero, Josep, additional, and Elez, Elena, additional

Published
2021
Full Text
View/download PDF

46. Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for RAS Mutations in Colorectal Cancer with a Single Metastasis Site: The METABEAM Study

Author

Kagawa, Yoshinori, primary, Elez, Elena, additional, García-Foncillas, Jesús, additional, Bando, Hideaki, additional, Taniguchi, Hiroya, additional, Vivancos, Ana, additional, Akagi, Kiwamu, additional, García, Ariadna, additional, Denda, Tadamichi, additional, Ros, Javier, additional, Nishina, Tomohiro, additional, Baraibar, Iosune, additional, Komatsu, Yoshito, additional, Ciardiello, Davide, additional, Oki, Eiji, additional, Kudo, Toshihiro, additional, Kato, Takeshi, additional, Yamanaka, Takeharu, additional, Tabernero, Josep, additional, and Yoshino, Takayuki, additional

Published
2021
Full Text
View/download PDF

48. Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells

Author

Baraibar, Iosune, primary, Roman, Marta, additional, Rodríguez-Remírez, María, additional, López, Inés, additional, Vilalta, Anna, additional, Guruceaga, Elisabeth, additional, Ecay, Margarita, additional, Collantes, María, additional, Lozano, Teresa, additional, Alignani, Diego, additional, Puyalto, Ander, additional, Oliver, Ana, additional, Ortiz-Espinosa, Sergio, additional, Moreno, Haritz, additional, Torregrosa, María, additional, Rolfo, Christian, additional, Caglevic, Christian, additional, García-Ros, David, additional, Villalba-Esparza, María, additional, De Andrea, Carlos, additional, Vicent, Silvestre, additional, Pío, Rubén, additional, Lasarte, Juan José, additional, Calvo, Alfonso, additional, Ajona, Daniel, additional, and Gil-Bazo, Ignacio, additional

Published
2020
Full Text
View/download PDF

50. The predictive role of plasma mutant allele fraction to antiangiogenic drugs in patients with mCRC: An expanded analysis of surrogate biomarkers of response to first-line treatment with bevacizumab.

Author

Martini, Giulia, primary, Elez, Elena, additional, Mancuso, Francesco M, additional, Gomez, Maria Auxiliadora, additional, Caratu, Ginevra, additional, Matito, Judit, additional, Argiles, Guillem, additional, Mulet, Nuria, additional, Baraibar, Iosune, additional, Ros, Javier, additional, Garcia, Ariadna, additional, Comas, Raquel, additional, Ligero, Marta, additional, Santos, Cristina, additional, Nuciforo, Paolo, additional, Dienstmann, Rodrigo, additional, Tabernero, Josep, additional, Aranda, Enrique, additional, Perez-Lopez, Raquel, additional, and Vivancos, Ana, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results